Type 1 diabetes cannot be fully prevented with any currently available method. Unlike type 2 diabetes, which is closely tied to lifestyle factors, type 1 is an autoimmune condition where the body’s immune system destroys the cells that produce insulin. However, the landscape has shifted significantly in recent years. It is now possible to screen for the disease years before symptoms appear and, in some cases, delay its onset by roughly two and a half years with an FDA-approved treatment.
Why Type 1 Diabetes Can’t Be Prevented Yet
Type 1 diabetes develops when the immune system mistakenly attacks the insulin-producing cells in the pancreas. The process is driven largely by genetics, particularly by specific immune-system genes. Siblings who share both high-risk gene variants have a 55% chance of developing type 1 diabetes by age 12, while siblings who share only one or none of those variants have about a 5% risk. In the general population, the rate is roughly 1 in 300.
Environmental factors also play a role, though researchers are still working out exactly which ones matter most. A major ongoing study called TEDDY (The Environmental Determinants of Diabetes in the Young) is tracking infections, diet, psychological stress, medications, immunizations, and even tap water composition to identify triggers that either set off or protect against the autoimmune process. So far, no single environmental factor has been confirmed as something you can reliably avoid to stop the disease from developing.
This is the core challenge: because the disease is rooted in an immune response shaped by genetics and poorly understood environmental triggers, there is no diet, supplement, exercise program, or lifestyle change proven to prevent it.
The Three Stages of Type 1 Diabetes
One of the most important developments in recent years is the recognition that type 1 diabetes doesn’t appear overnight. It progresses through three distinct stages, and the earlier stages can be detected long before a person feels sick.
- Stage 1: The immune system has begun attacking insulin-producing cells. Blood tests reveal two or more types of autoantibodies (immune proteins that signal the attack), but blood sugar levels are still normal and there are no symptoms.
- Stage 2: The immune attack has progressed enough that blood sugar levels become abnormal, though still not high enough to cause noticeable symptoms. Two or more autoantibodies are still present.
- Stage 3: This is what most people think of as a type 1 diabetes diagnosis. Blood sugar is high, symptoms like extreme thirst, frequent urination, and weight loss appear, and the person needs insulin.
The progression from stage 1 to stage 3 can take months or years. That window is where current prevention efforts are focused.
Screening for Early-Stage Disease
Because the autoimmune process starts silently, screening with a blood test for autoantibodies is the only way to catch type 1 diabetes in its early stages. The four autoantibodies doctors look for target insulin, an enzyme called glutamic acid decarboxylase, a protein called insulinoma-associated antigen-2, and a zinc transporter. Having two or more of these autoantibodies means the autoimmune process is underway.
If you have a family member with type 1 diabetes, you can get screened for free through TrialNet, a major research network. Screening is available at no cost for relatives ages 2 to 45 with a parent, sibling, or child who has type 1, and for relatives ages 2 to 20 with a grandparent, aunt, uncle, niece, nephew, or half-sibling with the disease. TrialNet offers in-home test kits, kits you can take to a local lab, or in-person appointments at their screening locations.
Early detection matters because it opens the door to treatment that can slow the disease, and it prevents the dangerous scenario where a child or adult is diagnosed only after they become seriously ill with diabetic ketoacidosis, a life-threatening emergency.
Teplizumab: The First FDA-Approved Delay Treatment
In 2022, the FDA approved teplizumab, the first treatment shown to delay the progression of type 1 diabetes. It works by calming the specific branch of the immune system that destroys insulin-producing cells. The treatment is a 14-day course of intravenous infusions, and it is approved for people age 8 and older who are in stage 2.
In clinical trials, teplizumab delayed the onset of stage 3 (symptomatic) type 1 diabetes by a median of about 32 months compared to a placebo. People who received the treatment went a median of nearly 5 years before developing clinical diabetes, compared to just over 2 years in the placebo group. That additional time means years without needing to manage insulin injections, count carbohydrates, or worry about blood sugar swings.
Teplizumab does not prevent type 1 diabetes permanently. Most people who receive it will still eventually progress to stage 3. But those extra years, especially for a child, can be significant for quality of life and development.
Other Treatments Under Investigation
Several clinical trials are currently testing whether other immune-modifying treatments can preserve insulin production or slow disease progression. TrialNet is running trials on combinations of drugs that target different parts of the immune response, including a study pairing two immunotherapy drugs to see if they can protect insulin-producing cells better than either one alone. Another trial is evaluating a class of drugs called JAK inhibitors, which dial down immune signaling. A third is testing whether a low dose of a treatment called ATG can prevent or delay progression from early-stage to symptomatic disease.
Outside of immunotherapy, researchers have found that a common blood pressure medication called verapamil may help preserve the function of insulin-producing cells in people who were recently diagnosed. In studies, people taking verapamil maintained higher levels of their own insulin production during the first year after diagnosis compared to those on placebo. This doesn’t prevent type 1 diabetes, but preserving even a small amount of natural insulin production makes the disease easier to manage and reduces the risk of dangerous blood sugar lows.
What You Can Do Right Now
If type 1 diabetes runs in your family, the most concrete step you can take is screening. Identifying autoantibodies in a child or young adult before symptoms appear gives you time to monitor, access treatments like teplizumab if the disease reaches stage 2, and potentially enroll in clinical trials testing newer interventions. It also means that if stage 3 does arrive, you and your medical team are prepared rather than caught off guard by an emergency.
For people with no family history, there is currently no routine screening recommendation, though research groups are exploring whether population-wide screening in children could be beneficial. About 85% of people diagnosed with type 1 diabetes have no close family member with the disease, which is why broader screening programs are an active area of discussion.
There are no proven dietary changes, vitamins, or lifestyle modifications that prevent type 1 diabetes. Claims about avoiding cow’s milk, gluten, or specific foods have been studied, but none have produced consistent evidence of protection. The most effective tools available today are early detection and immune-targeted therapies, and both are advancing rapidly.